ZVSA (ZyVersa Therapeutics) Short Interest


ZVSA ZyVersa Therapeutics Inc ZVSA
30 GF Score
Price $0.16
! 1 Warning Sign
View Full Analysis

What is ZyVersa Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

ZVSA vs CLSDQ, ADAPY, BPTH: Short Interest Comparison

For the Biotechnology subindustry, ZyVersa Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ZyVersa Therapeutics Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ZyVersa Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where ZyVersa Therapeutics's Short Interest falls into.


ZVSA
30GF Score
ZyVersa Therapeutics Inc ZVSA
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ZyVersa Therapeutics Business Description

Address 2200 North Commerce Parkway, Suite 208, Weston, FL, USA, 33326
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.
30GF Score

Get the complete analysis for ZVSA

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.16
Price